A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

NCT03210961 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

109

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: PF-06826647 tablet
DRUG: PF-06826647 oral suspension
OTHER: Placebo oral solution/suspension
OTHER: Placebo tablet

Sponsor

Pfizer